TTX

Triterpenoid Therapeutics

Opportunity

A seed-stage pharmaceutical company founded in 2018 with a commitment to developing effective therapies for incurable cancers, chronic diseases like Parkinson’s, and anti-viral use against COVID-19. Offering a fundamentally different approach to treating these diseases by developing therapies that target cell networks and tumor microenvironments instead of “Single Target” drugs.

TTX holds exclusive license rights from Dartmouth College on a pipeline of over 14 synthetic triterpenoid drugs discovered by company founder,  modeled in part on the healing-powers of oleanic acid most commonly found in olives.

Founded by cancer research pioneer, Michael B. Sporn, MD.  Internationally recognized for a career dedicated to research, discovery, and design of innovative therapeutics. Emeritus Professor of Pharmacology and Medicine at the Geisel School of Medicine at Dartmouth College and Former Laboratory Chief at National Cancer Institute (NIH).  With ongoing research being conducted at The Case Western Reserve, University School of Medicine, Tohoku University (Japan), University of Liverpool (UK) , and Uppsala University (Sweden).

Approach

• Articulated Company brand positioning, value proposition, creative, messaging and story — developed new website for use in briefing scientific/innovation partners + funding resources

• Developed pitch-deck for grant applications/Investor meetings – Science Team has won multiple Small Business Innovation Research (SBIR) Awards to date

• Exciting new findings from animal testing demonstrating success in killing/inhibiting cancerous brain tumors — Multiple new Grants pending along with updates to marketing materials

Results

• Awarded multiple peer-reviewed National Institutes of Health SBIR Grants, with additional grants pending

• Scientific findings in exciting this new class of chronic disease therapeutics gaining recognition and support for commercial success